Pfizer Lipitor Patent Fails PTO Reexamination
In an initial office action, the U.S. Patent and Trademark Office rejects the claims in Lipitor’s basic patent.
In an initial office action, the U.S. Patent and Trademark Office rejects the claims in Lipitor’s basic patent.